StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 19 Jan 2024 04:22:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday InDex Pharmaceuticals announces expected cash balance per March 31, 2024 http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Fri, 19 Jan 2024 04:22:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces expected cash balance per March 31, 2024 http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Fri, 19 Jan 2024 04:22:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces expected cash balance per March 31, 2024 http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Fri, 19 Jan 2024 04:22:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces expected cash balance per March 31, 2024 http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Fri, 19 Jan 2024 04:22:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces expected cash balance per March 31, 2024 http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Fri, 19 Jan 2024 04:22:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces expected cash balance per March 31, 2024 http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+expected+cash+balance+per+March+31%2C+2024/22648498.html Fri, 19 Jan 2024 04:22:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Fri, 20 Oct 2023 08:28:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Fri, 20 Oct 2023 08:28:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Fri, 20 Oct 2023 08:28:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Fri, 20 Oct 2023 08:28:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Fri, 20 Oct 2023 08:28:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+has+been+granted+a+new+patent+for+cobitolimod+in+South+Korea/22294520.html Fri, 20 Oct 2023 08:28:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Wed, 11 Oct 2023 02:46:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Wed, 11 Oct 2023 02:46:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Wed, 11 Oct 2023 02:46:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Wed, 11 Oct 2023 02:46:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Wed, 11 Oct 2023 02:46:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+announces+that+all+patients+needed+for+the+cobitolimod+dose+selection+milestone+have+completed+Induction+Study+1+of+the+phase+III+program+CONCLUDE/22259428.html Wed, 11 Oct 2023 02:46:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals is attending the UEGW 2023 congress http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Thu, 05 Oct 2023 06:16:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals is attending the UEGW 2023 congress http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Thu, 05 Oct 2023 06:16:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals is attending the UEGW 2023 congress http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html for the full story. http://www.streetinsider.com/Press+Releases/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Thu, 05 Oct 2023 06:16:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals is attending the UEGW 2023 congress http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Thu, 05 Oct 2023 06:16:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals is attending the UEGW 2023 congress http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Thu, 05 Oct 2023 06:16:00 -0500 INDEX INDEX O.29165783 InDex Pharmaceuticals is attending the UEGW 2023 congress http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html for the full story. http://www.streetinsider.com/PRNewswire/InDex+Pharmaceuticals+is+attending+the+UEGW+2023+congress/22241751.html Thu, 05 Oct 2023 06:16:00 -0500 INDEX INDEX O.29165783 'Positive results from PK study with cobitolimod' selected as one of the best abstracts for poster presentation at UEGW: InDex Pharmaceuticals http://www.streetinsider.com/Press+Releases/%27Positive+results+from+PK+study+with+cobitolimod%27+selected+as+one+of+the+best+abstracts+for+poster+presentation+at+UEGW%3A+InDex+Pharmaceuticals/22071940.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/%27Positive+results+from+PK+study+with+cobitolimod%27+selected+as+one+of+the+best+abstracts+for+poster+presentation+at+UEGW%3A+InDex+Pharmaceuticals/22071940.html for the full story. http://www.streetinsider.com/Press+Releases/%27Positive+results+from+PK+study+with+cobitolimod%27+selected+as+one+of+the+best+abstracts+for+poster+presentation+at+UEGW%3A+InDex+Pharmaceuticals/22071940.html Tue, 22 Aug 2023 04:08:00 -0500 INDEX INDEX O.29165783